drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00427 | DB14509 | 1,233 | 1,399 | [
"DDInter1879",
"DDInter1081"
] | Triprolidine | Lithium carbonate | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1233,
24,
1399
]
],
[
[
1233,
24,
506
],
[
506,
24,
1399
]
],
[
[
1233,
63,
475
],
[
475,
24,
1399
]
],
[
[
1233,
24,
222
],
[
222,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB08880 | DB11921 | 1,510 | 1,019 | [
"DDInter1771",
"DDInter492"
] | Teriflunomide | Deflazacort | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1510,
25,
1019
]
],
[
[
1510,
64,
1072
],
[
1072,
23,
1019
]
],
[
[
1510,
23,
1193
],
[
1193,
23,
1019
]
],
[
[
1510,
62,
1461
],
[
14... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"... | Teriflunomide may lead to a major life threatening interaction when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate m... |
DB00005 | DB09322 | 1,057 | 1,114 | [
"DDInter687",
"DDInter1966"
] | Etanercept | Zinc sulfate | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
1057,
23,
1114
]
],
[
[
1057,
24,
66
],
[
66,
23,
1114
]
],
[
[
1057,
25,
1093
],
[
1093,
62,
1114
]
],
[
[
1057,
25,
1394
],
[
1394,
... | [
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Etanercept may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause ... |
DB00262 | DB11601 | 552 | 1,270 | [
"DDInter302",
"DDInter1889"
] | Carmustine | Tuberculin purified protein derivative | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
552,
24,
1270
]
],
[
[
552,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
552,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
552,
63,
599
],
[
599,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Carmustine may lead to a major life threatening interaction when taken with Cladri... |
DB00783 | DB01041 | 1,438 | 770 | [
"DDInter679",
"DDInter1789"
] | Estradiol | Thalidomide | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
1438,
25,
770
]
],
[
[
1438,
64,
1668
],
[
1668,
1,
770
]
],
[
[
1438,
18,
2637
],
[
2637,
45,
770
]
],
[
[
1438,
6,
7524
],
[
7524,
... | [
[
[
"Estradiol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Estradiol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u... | Estradiol may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Estradiol (Compound) downregulates FGFR2 (Gene) and FGFR2 (Gene) is bound by Thalidomide (Compound)
Estradiol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by ... |
DB00352 | DB09079 | 482 | 1,496 | [
"DDInter1814",
"DDInter1296"
] | Tioguanine | Nintedanib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
482,
24,
1496
]
],
[
[
482,
24,
33
],
[
33,
24,
1496
]
],
[
[
482,
24,
1412
],
[
1412,
63,
1496
]
],
[
[
482,
63,
305
],
[
305,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol an... |
DB04946 | DB11718 | 924 | 927 | [
"DDInter907",
"DDInter640"
] | Iloperidone | Encorafenib | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
924,
25,
927
]
],
[
[
924,
62,
112
],
[
112,
23,
927
]
],
[
[
924,
24,
720
],
[
720,
24,
927
]
],
[
[
924,
63,
1324
],
[
1324,
2... | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Iloperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Iloperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB01175 | DB11837 | 318 | 1,297 | [
"DDInter672",
"DDInter1351"
] | Escitalopram | Osilodrostat | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
318,
25,
1297
]
],
[
[
318,
62,
112
],
[
112,
23,
1297
]
],
[
[
318,
64,
222
],
[
222,
23,
1297
]
],
[
[
318,
24,
578
],
[
578,
... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Escitalopram may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine ... |
DB00284 | DB00635 | 1,647 | 1,573 | [
"DDInter11",
"DDInter1515"
] | Acarbose | Prednisone | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1647,
24,
1573
]
],
[
[
1647,
24,
175
],
[
175,
40,
1573
]
],
[
[
1647,
23,
1103
],
[
1103,
1,
1573
]
],
[
[
1647,
24,
251
],
[
251,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Acarbose may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) resembles Prednisone (Compound)
... |
DB00916 | DB08901 | 112 | 1,468 | [
"DDInter1202",
"DDInter1492"
] | Metronidazole | Ponatinib | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
112,
24,
1468
]
],
[
[
112,
23,
478
],
[
478,
24,
1468
]
],
[
[
112,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
112,
7,
16981
],
[
16981,
... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
],
[
... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Metronidazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Metronidazole (Com... |
DB00347 | DB00748 | 917 | 662 | [
"DDInter1871",
"DDInter297"
] | Trimethadione | Carbinoxamine | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
917,
24,
662
]
],
[
[
917,
24,
1594
],
[
1594,
24,
662
]
],
[
[
917,
6,
6017
],
[
6017,
45,
662
]
],
[
[
917,
21,
28769
],
[
28769,
... | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Trimethadione (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound)
Trimet... |
DB01234 | DB09074 | 1,220 | 1,362 | [
"DDInter513",
"DDInter1327"
] | Dexamethasone | Olaparib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
1220,
25,
1362
]
],
[
[
1220,
24,
627
],
[
627,
63,
1362
]
],
[
[
1220,
64,
576
],
[
576,
24,
1362
]
],
[
[
1220,
24,
1683
],
[
1683,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
],
[
"Bicte... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Dexamethasone may lead to a major life threatening interaction when taken with Methadone and Methadone may ca... |
DB06589 | DB11732 | 1,250 | 1,097 | [
"DDInter1400",
"DDInter1027"
] | Pazopanib | Lasmiditan | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1250,
24,
1097
]
],
[
[
1250,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
1250,
24,
971
],
[
971,
63,
1097
]
],
[
[
1250,
64,
478
],
[
478,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilt... |
DB00995 | DB08870 | 1,112 | 850 | [
"DDInter139",
"DDInter228"
] | Auranofin | Brentuximab vedotin | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1112,
24,
850
]
],
[
[
1112,
63,
896
],
[
896,
24,
850
]
],
[
[
1112,
24,
1468
],
[
1468,
63,
850
]
],
[
[
1112,
24,
980
],
[
980,
... | [
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
... | Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Po... |
DB01218 | DB05294 | 1,493 | 1,069 | [
"DDInter852",
"DDInter1917"
] | Halofantrine | Vandetanib | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1493,
25,
1069
]
],
[
[
1493,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
1493,
21,
28921
],
[
28921,
60,
1069
]
],
[
[
1493,
62,
1247
],
[
1... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Halofantrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Van... | Halofantrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Halofantrine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Vandetanib (Compound)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazol... |
DB00635 | DB11003 | 1,573 | 748 | [
"DDInter1515",
"DDInter100"
] | Prednisone | Anthrax vaccine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1573,
24,
748
]
],
[
[
1573,
25,
676
],
[
676,
63,
748
]
],
[
[
1573,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1573,
24,
1619
],
[
1619,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upa... | Prednisone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab... |
DB04951 | DB06603 | 187 | 39 | [
"DDInter1477",
"DDInter1387"
] | Pirfenidone | Panobinostat | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
187,
24,
39
]
],
[
[
187,
63,
912
],
[
912,
24,
39
]
],
[
[
187,
24,
1627
],
[
1627,
63,
39
]
],
[
[
187,
24,
655
],
[
655,
24,
... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with C... |
DB01044 | DB01276 | 246 | 123 | [
"DDInter809",
"DDInter706"
] | Gatifloxacin | Exenatide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Major | 2 | [
[
[
246,
25,
123
]
],
[
[
246,
64,
1573
],
[
1573,
24,
123
]
],
[
[
246,
1,
1539
],
[
1539,
24,
123
]
],
[
[
246,
25,
820
],
[
820,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Exenatide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u... | Gatifloxacin may lead to a major life threatening interaction when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Gatifloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate di... |
DB01268 | DB14723 | 1,151 | 159 | [
"DDInter1731",
"DDInter1026"
] | Sunitinib | Larotrectinib | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1151,
24,
159
]
],
[
[
1151,
63,
479
],
[
479,
23,
159
]
],
[
[
1151,
64,
318
],
[
318,
23,
159
]
],
[
[
1151,
25,
1375
],
[
1375,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Sunitinib may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause... |
DB00938 | DB06595 | 455 | 1,491 | [
"DDInter1635",
"DDInter1214"
] | Salmeterol | Midostaurin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
455,
24,
1491
]
],
[
[
455,
24,
761
],
[
761,
24,
1491
]
],
[
[
455,
63,
888
],
[
888,
24,
1491
]
],
[
[
455,
24,
927
],
[
927,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamo... |
DB00686 | DB08816 | 383 | 578 | [
"DDInter1424",
"DDInter1802"
] | Pentosan polysulfate | Ticagrelor | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
383,
24,
578
]
],
[
[
383,
21,
28762
],
[
28762,
60,
578
]
],
[
[
383,
63,
1578
],
[
1578,
24,
578
]
],
[
[
383,
24,
1347
],
[
1347,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Pentosan polysulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Si... | Pentosan polysulfate (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when ta... |
DB01125 | DB01254 | 279 | 1,213 | [
"DDInter98",
"DDInter484"
] | Anisindione | Dasatinib | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
279,
25,
1213
]
],
[
[
279,
64,
112
],
[
112,
23,
1213
]
],
[
[
279,
24,
738
],
[
738,
63,
1213
]
],
[
[
279,
62,
467
],
[
467,
... | [
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
... | Anisindione may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cau... |
DB01225 | DB15233 | 500 | 1,650 | [
"DDInter645",
"DDInter142"
] | Enoxaparin | Avapritinib | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
500,
25,
1650
]
],
[
[
500,
24,
557
],
[
557,
24,
1650
]
],
[
[
500,
63,
1039
],
[
1039,
24,
1650
]
],
[
[
500,
64,
1512
],
[
1512,
... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deo... | Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfl... |
DB00015 | DB08896 | 582 | 292 | [
"DDInter1585",
"DDInter1576"
] | Reteplase | Regorafenib | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
582,
25,
292
]
],
[
[
582,
24,
643
],
[
643,
24,
292
]
],
[
[
582,
24,
41
],
[
41,
63,
292
]
],
[
[
582,
25,
553
],
[
553,
25,
... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenl... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipra... |
DB00834 | DB01211 | 932 | 609 | [
"DDInter1215",
"DDInter393"
] | Mifepristone | Clarithromycin | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
932,
25,
609
]
],
[
[
932,
6,
4973
],
[
4973,
45,
609
]
],
[
[
932,
7,
3466
],
[
3466,
46,
609
]
],
[
[
932,
7,
8733
],
[
8733,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Mifepristone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"C... | Mifepristone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Mifepristone (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Clarithromycin (Compound)
Mifepristone (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Clarithromycin (Compound)
... |
DB00656 | DB08865 | 827 | 1,593 | [
"DDInter1851",
"DDInter448"
] | Trazodone | Crizotinib | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
827,
25,
1593
]
],
[
[
827,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
827,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
827,
24,
283
],
[
283,
... | [
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Trazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotini... | Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Trazodone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib ... |
DB01009 | DB01124 | 935 | 1,411 | [
"DDInter1009",
"DDInter1828"
] | Ketoprofen | Tolbutamide | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
935,
24,
1411
]
],
[
[
935,
24,
959
],
[
959,
40,
1411
]
],
[
[
935,
63,
245
],
[
245,
40,
1411
]
],
[
[
935,
6,
10612
],
[
10612,
... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00713 | DB00759 | 1,138 | 1,620 | [
"DDInter1354",
"DDInter1783"
] | Oxacillin | Tetracycline | An antibiotic similar to [flucloxacillin] used in resistant staphylococci infections. | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Moderate | 1 | [
[
[
1138,
24,
1620
]
],
[
[
1138,
63,
1572
],
[
1572,
40,
1620
]
],
[
[
1138,
24,
1669
],
[
1669,
40,
1620
]
],
[
[
1138,
63,
126
],
[
126... | [
[
[
"Oxacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Oxacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
... | Oxacillin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Oxacillin may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Tetracycline... |
DB00748 | DB11915 | 662 | 1,293 | [
"DDInter297",
"DDInter1909"
] | Carbinoxamine | Valbenazine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
662,
24,
1293
]
],
[
[
662,
24,
516
],
[
516,
24,
1293
]
],
[
[
662,
35,
832
],
[
832,
24,
1293
]
],
[
[
662,
63,
1219
],
[
1219,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Carbinoxamine (Compound) resembles Tripelennamine (Compound) and Carbinoxamine may cause a moderate ... |
DB08889 | DB14443 | 350 | 987 | [
"DDInter299",
"DDInter1931"
] | Carfilzomib | Vibrio cholerae CVD 103-HgR strain live antigen | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
350,
24,
987
]
],
[
[
350,
24,
1480
],
[
1480,
24,
987
]
],
[
[
350,
63,
1488
],
[
1488,
24,
987
]
],
[
[
350,
64,
581
],
[
581,
... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Carfilzomib may cause a moderate interaction that could exacerbate diseases wh... |
DB00465 | DB00501 | 886 | 752 | [
"DDInter1010",
"DDInter380"
] | Ketorolac | Cimetidine | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Minor | 0 | [
[
[
886,
23,
752
]
],
[
[
886,
21,
29134
],
[
29134,
60,
752
]
],
[
[
886,
1,
935
],
[
935,
62,
752
]
],
[
[
886,
25,
256
],
[
256,
... | [
[
[
"Ketorolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Ketorolac",
"{u} (Compound) causes {v} (Side Effect)",
"Flatulence"
],
[
"Flatulence",
"{u} (Side Effect) is caused... | Ketorolac (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Ketorolac (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Ketorolac may lead to a major life threatening... |
DB00295 | DB00652 | 475 | 234 | [
"DDInter1244",
"DDInter1421"
] | Morphine | Pentazocine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Major | 2 | [
[
[
475,
25,
234
]
],
[
[
475,
25,
1359
],
[
1359,
40,
234
]
],
[
[
475,
40,
197
],
[
197,
1,
234
]
],
[
[
475,
6,
7940
],
[
7940,
4... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentazocine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dezocine"
],
[
"Dezocine",
"{u} (Compoun... | Morphine may lead to a major life threatening interaction when taken with Dezocine and Dezocine (Compound) resembles Pentazocine (Compound)
Morphine (Compound) resembles Levorphanol (Compound) and Levorphanol (Compound) resembles Pentazocine (Compound)
Morphine (Compound) binds OPRK1 (Gene) and OPRK1 (Gene) is bound by... |
DB00026 | DB00928 | 1,184 | 1,426 | [
"DDInter94",
"DDInter148"
] | Anakinra | Azacitidine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Moderate | 1 | [
[
[
1184,
24,
1426
]
],
[
[
1184,
24,
1238
],
[
1238,
40,
1426
]
],
[
[
1184,
24,
372
],
[
372,
1,
1426
]
],
[
[
1184,
25,
1064
],
[
1064,... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin (Compound) resembles Azacitidine (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Azacitidine (Compound... |
DB04948 | DB09112 | 1,084 | 1,455 | [
"DDInter1083",
"DDInter1306"
] | Lofexidine | Nitrous acid | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1084,
24,
1455
]
],
[
[
1084,
40,
1020
],
[
1020,
24,
1455
]
],
[
[
1084,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1084,
63,
885
],
[
885... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Lofexidine",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
],
[
"Clonidine",
"{u} may cause a moderat... | Lofexidine (Compound) resembles Clonidine (Compound) and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that... |
DB09054 | DB12130 | 384 | 1,017 | [
"DDInter905",
"DDInter1094"
] | Idelalisib | Lorlatinib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
384,
25,
1017
]
],
[
[
384,
63,
608
],
[
608,
23,
1017
]
],
[
[
384,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
384,
62,
271
],
[
271,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsav... |
DB04865 | DB06603 | 4 | 39 | [
"DDInter1335",
"DDInter1387"
] | Omacetaxine mepesuccinate | Panobinostat | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
4,
24,
39
]
],
[
[
4,
63,
1257
],
[
1257,
24,
39
]
],
[
[
4,
24,
221
],
[
221,
63,
39
]
],
[
[
4,
24,
1683
],
[
1683,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases... |
DB00860 | DB01021 | 891 | 674 | [
"DDInter1513",
"DDInter1861"
] | Prednisolone | Trichlormethiazide | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
891,
24,
674
]
],
[
[
891,
63,
1014
],
[
1014,
40,
674
]
],
[
[
891,
24,
178
],
[
178,
1,
674
]
],
[
[
891,
24,
359
],
[
359,
40... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Tr... |
DB09073 | DB11817 | 951 | 1,259 | [
"DDInter1379",
"DDInter165"
] | Palbociclib | Baricitinib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
951,
25,
1259
]
],
[
[
951,
24,
949
],
[
949,
24,
1259
]
],
[
[
951,
63,
563
],
[
563,
24,
1259
]
],
[
[
951,
24,
1129
],
[
1129,
... | [
[
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Palbocicli... |
DB00912 | DB01577 | 473 | 1,529 | [
"DDInter1581",
"DDInter1161"
] | Repaglinide | Metamfetamine | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Moderate | 1 | [
[
[
473,
24,
1529
]
],
[
[
473,
63,
939
],
[
939,
40,
1529
]
],
[
[
473,
24,
1161
],
[
1161,
40,
1529
]
],
[
[
473,
24,
22
],
[
22,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Metamfetami... |
DB08912 | DB09104 | 1,040 | 286 | [
"DDInter462",
"DDInter1118"
] | Dabrafenib | Magnesium hydroxide | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1040,
24,
286
]
],
[
[
1040,
63,
481
],
[
481,
23,
286
]
],
[
[
1040,
64,
263
],
[
263,
23,
286
]
],
[
[
1040,
63,
859
],
[
859,
... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
... | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Dabrafenib may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a... |
DB00653 | DB12615 | 544 | 1,381 | [
"DDInter1120",
"DDInter1482"
] | Magnesium sulfate | Plazomicin | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Major | 2 | [
[
[
544,
25,
1381
]
],
[
[
544,
25,
416
],
[
416,
24,
1381
]
],
[
[
544,
25,
416
],
[
416,
62,
608
],
[
608,
23,
1381
]
],
[
[
544,
... | [
[
[
"Magnesium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Magnesium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
... | Magnesium sulfate may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Magnesium sulfate may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a min... |
DB00087 | DB09054 | 599 | 384 | [
"DDInter41",
"DDInter905"
] | Alemtuzumab | Idelalisib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
599,
24,
384
]
],
[
[
599,
24,
725
],
[
725,
63,
384
]
],
[
[
599,
24,
328
],
[
328,
24,
384
]
],
[
[
599,
63,
305
],
[
305,
24,... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine ... |
DB00196 | DB00912 | 600 | 473 | [
"DDInter743",
"DDInter1581"
] | Fluconazole | Repaglinide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
600,
24,
473
]
],
[
[
600,
6,
8374
],
[
8374,
45,
473
]
],
[
[
600,
21,
29386
],
[
29386,
60,
473
]
],
[
[
600,
24,
798
],
[
798,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Fluconazole (Compound) causes Cardiovascular disorder (Side Effect) and Cardiovascular disorder (Side Effect) is caused by Repaglinide (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases wh... |
DB00612 | DB00712 | 1,121 | 1,274 | [
"DDInter216",
"DDInter763"
] | Bisoprolol | Flurbiprofen | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
1121,
24,
1274
]
],
[
[
1121,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
1121,
63,
752
],
[
752,
23,
1274
]
],
[
[
1121,
1,
88
],
[
88,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Bisoprolol",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side... | Bisoprolol (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when take... |
DB06772 | DB12240 | 310 | 110 | [
"DDInter259",
"DDInter1485"
] | Cabazitaxel | Polatuzumab vedotin | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
310,
24,
110
]
],
[
[
310,
24,
129
],
[
129,
23,
110
]
],
[
[
310,
63,
467
],
[
467,
24,
110
]
],
[
[
310,
24,
578
],
[
578,
24,... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Simvasta... |
DB00398 | DB00738 | 79 | 485 | [
"DDInter1702",
"DDInter1420"
] | Sorafenib | Pentamidine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
79,
24,
485
]
],
[
[
79,
24,
1423
],
[
1423,
1,
485
]
],
[
[
79,
6,
12523
],
[
12523,
45,
485
]
],
[
[
79,
6,
5295
],
[
5295,
46... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene and Ospemifene (Compound) resembles Pentamidine (Compound)
Sorafenib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Sorafenib (Compound) binds CDK7 (Gene) and CDK7 (Gene) is upregula... |
DB00661 | DB01088 | 122 | 714 | [
"DDInter1928",
"DDInter908"
] | Verapamil | Iloprost | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
122,
24,
714
]
],
[
[
122,
24,
1479
],
[
1479,
24,
714
]
],
[
[
122,
63,
1648
],
[
1648,
24,
714
]
],
[
[
122,
24,
1450
],
[
1450,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Aldes... |
DB01072 | DB06228 | 915 | 792 | [
"DDInter129",
"DDInter1609"
] | Atazanavir | Rivaroxaban | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
915,
24,
792
]
],
[
[
915,
6,
4973
],
[
4973,
45,
792
]
],
[
[
915,
21,
28703
],
[
28703,
60,
792
]
],
[
[
915,
64,
752
],
[
752,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Atazanavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rivaroxaban (Compound)
Atazanavir (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Atazanavir may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause ... |
DB00054 | DB00328 | 1,432 | 831 | [
"DDInter6",
"DDInter921"
] | Abciximab | Indomethacin | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Moderate | 1 | [
[
[
1432,
24,
831
]
],
[
[
1432,
24,
24
],
[
24,
1,
831
]
],
[
[
1432,
24,
848
],
[
848,
63,
831
]
],
[
[
1432,
64,
20
],
[
20,
24,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
],
[
... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) resembles Indomethacin (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exace... |
DB09134 | DB15066 | 1,552 | 445 | [
"DDInter966",
"DDInter821"
] | Ioversol | Givosiran | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Major | 2 | [
[
[
1552,
25,
445
]
],
[
[
1552,
64,
589
],
[
589,
24,
445
]
],
[
[
1552,
64,
629
],
[
629,
25,
445
]
],
[
[
1552,
64,
589
],
[
589,
... | [
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may caus... | Ioversol may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Ioversol may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threateni... |
DB00563 | DB01268 | 663 | 1,151 | [
"DDInter1174",
"DDInter1731"
] | Methotrexate | Sunitinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
663,
24,
1151
]
],
[
[
663,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
663,
7,
2635
],
[
2635,
45,
1151
]
],
[
[
663,
18,
9650
],
[
9650,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Methotrexate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Methotrexate (Compound) upregulates MYLK (Gene) and MYLK (Gene) is bound by Sunitinib (Compound)
Methotrexate (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Sunitinib (Compound)
Methotrexate (Compoun... |
DB00393 | DB00712 | 854 | 1,274 | [
"DDInter1295",
"DDInter763"
] | Nimodipine | Flurbiprofen | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
854,
24,
1274
]
],
[
[
854,
21,
28784
],
[
28784,
60,
1274
]
],
[
[
854,
24,
752
],
[
752,
23,
1274
]
],
[
[
854,
1,
1081
],
[
1081,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side... | Nimodipine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Flurbiprofen (Compound)
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when take... |
DB00867 | DB08899 | 1,052 | 129 | [
"DDInter1606",
"DDInter649"
] | Ritodrine | Enzalutamide | Adrenergic beta-agonist used to control premature labor. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1052,
24,
129
]
],
[
[
1052,
24,
918
],
[
918,
1,
129
]
],
[
[
1052,
63,
79
],
[
79,
24,
129
]
],
[
[
1052,
24,
1148
],
[
1148,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that cou... |
DB00193 | DB00342 | 534 | 1,181 | [
"DDInter1841",
"DDInter1770"
] | Tramadol | Terfenadine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Moderate | 1 | [
[
[
534,
24,
1181
]
],
[
[
534,
23,
112
],
[
112,
62,
1181
]
],
[
[
534,
24,
1387
],
[
1387,
62,
1181
]
],
[
[
534,
24,
286
],
[
286,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Terfenadine
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Terbinafine and Terbin... |
DB00884 | DB11348 | 1,008 | 1,065 | [
"DDInter1604",
"DDInter279"
] | Risedronic acid | Calcium Phosphate | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1008,
24,
1065
]
],
[
[
1008,
40,
1199
],
[
1199,
24,
1065
]
],
[
[
1008,
40,
1199
],
[
1199,
40,
1485
],
[
1485,
24,
1065
]
],
[
[
10... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Risedronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} ... | Risedronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Risedronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate (Compound) resembles Alendronic acid (Compound) and Alendronic acid ma... |
DB09074 | DB12130 | 1,362 | 1,017 | [
"DDInter1327",
"DDInter1094"
] | Olaparib | Lorlatinib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
1362,
25,
1017
]
],
[
[
1362,
63,
608
],
[
608,
23,
1017
]
],
[
[
1362,
64,
976
],
[
976,
24,
1017
]
],
[
[
1362,
63,
1554
],
[
1554,
... | [
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Olaparib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a mode... |
DB00675 | DB06717 | 888 | 875 | [
"DDInter1744",
"DDInter778"
] | Tamoxifen | Fosaprepitant | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
888,
24,
875
]
],
[
[
888,
63,
723
],
[
723,
1,
875
]
],
[
[
888,
21,
29340
],
[
29340,
60,
875
]
],
[
[
888,
63,
1101
],
[
1101,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Tamoxifen (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Fosaprepitant (Compound)
Tamoxifen ... |
DB00461 | DB04932 | 598 | 1,564 | [
"DDInter1254",
"DDInter491"
] | Nabumetone | Defibrotide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Moderate | 1 | [
[
[
598,
24,
1564
]
],
[
[
598,
24,
1039
],
[
1039,
24,
1564
]
],
[
[
598,
24,
738
],
[
738,
63,
1564
]
],
[
[
598,
63,
1061
],
[
1061,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Niraparib ... |
DB13915 | DB15091 | 689 | 676 | [
"DDInter146",
"DDInter1901"
] | Axicabtagene ciloleucel | Upadacitinib | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express ant... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
689,
25,
676
]
],
[
[
689,
63,
1430
],
[
1430,
24,
676
]
],
[
[
689,
63,
1184
],
[
1184,
25,
676
]
],
[
[
689,
64,
1064
],
[
1064,
... | [
[
[
"Axicabtagene ciloleucel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Axicabtagene ciloleucel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
... | Axicabtagene ciloleucel may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Axicabtagene ciloleucel may cause a moderate interaction that could exacerbate diseases when ... |
DB01236 | DB12141 | 679 | 971 | [
"DDInter1664",
"DDInter817"
] | Sevoflurane | Gilteritinib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
679,
24,
971
]
],
[
[
679,
62,
112
],
[
112,
23,
971
]
],
[
[
679,
63,
485
],
[
485,
24,
971
]
],
[
[
679,
24,
823
],
[
823,
63,... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Sevoflurane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and... |
DB00773 | DB14443 | 896 | 987 | [
"DDInter702",
"DDInter1931"
] | Etoposide | Vibrio cholerae CVD 103-HgR strain live antigen | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
896,
24,
987
]
],
[
[
896,
24,
1480
],
[
1480,
24,
987
]
],
[
[
896,
63,
141
],
[
141,
24,
987
]
],
[
[
896,
64,
581
],
[
581,
2... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Etoposide may cause a moderate interaction that could exacerbate diseases when t... |
DB00563 | DB03754 | 663 | 1,400 | [
"DDInter1174",
"DDInter1883"
] | Methotrexate | Tromethamine | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th e... | Minor | 0 | [
[
[
663,
23,
1400
]
],
[
[
663,
63,
964
],
[
964,
24,
1400
]
],
[
[
663,
24,
1669
],
[
1669,
24,
1400
]
],
[
[
663,
25,
972
],
[
972,
... | [
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tromethamine"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline a... |
DB01362 | DB06016 | 497 | 1,508 | [
"DDInter960",
"DDInter300"
] | Iohexol | Cariprazine | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Major | 2 | [
[
[
497,
25,
1508
]
],
[
[
497,
25,
913
],
[
913,
63,
1508
]
],
[
[
497,
64,
1220
],
[
1220,
24,
1508
]
],
[
[
497,
64,
475
],
[
475,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may ... | Iohexol may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Iohexol may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate i... |
DB00722 | DB01377 | 743 | 1,283 | [
"DDInter1079",
"DDInter1119"
] | Lisinopril | Magnesium oxide | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
743,
23,
1283
]
],
[
[
743,
24,
167
],
[
167,
23,
1283
]
],
[
[
743,
63,
1573
],
[
1573,
23,
1283
]
],
[
[
743,
40,
1638
],
[
1638,
... | [
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone... |
DB00081 | DB01175 | 273 | 318 | [
"DDInter1838",
"DDInter672"
] | Tositumomab | Escitalopram | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
273,
24,
318
]
],
[
[
273,
24,
1230
],
[
1230,
1,
318
]
],
[
[
273,
24,
597
],
[
597,
23,
318
]
],
[
[
273,
24,
384
],
[
384,
62... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a minor interaction... |
DB00414 | DB01319 | 590 | 34 | [
"DDInter16",
"DDInter777"
] | Acetohexamide | Fosamprenavir | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
590,
24,
34
]
],
[
[
590,
24,
1091
],
[
1091,
40,
34
]
],
[
[
590,
24,
609
],
[
609,
23,
34
]
],
[
[
590,
24,
1144
],
[
1144,
24... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interact... |
DB00690 | DB09098 | 1,216 | 98 | [
"DDInter762",
"DDInter1700"
] | Flurazepam | Somatrem | A benzodiazepine derivative used mainly as a hypnotic. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1216,
24,
98
]
],
[
[
1216,
63,
608
],
[
608,
23,
98
]
],
[
[
1216,
24,
159
],
[
159,
63,
98
]
],
[
[
1216,
24,
609
],
[
609,
24... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrect... |
DB00556 | DB11057 | 1,262 | 720 | [
"DDInter1429",
"DDInter1223"
] | Perflutren | Mineral oil | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1262,
24,
720
]
],
[
[
1262,
24,
927
],
[
927,
63,
720
]
],
[
[
1262,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1262,
25,
1069
],
[
1069,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suni... |
DB06228 | DB11703 | 792 | 405 | [
"DDInter1609",
"DDInter9"
] | Rivaroxaban | Acalabrutinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
792,
25,
405
]
],
[
[
792,
63,
1051
],
[
1051,
24,
405
]
],
[
[
792,
24,
643
],
[
643,
24,
405
]
],
[
[
792,
24,
982
],
[
982,
6... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with De... |
DB00722 | DB01234 | 743 | 1,220 | [
"DDInter1079",
"DDInter513"
] | Lisinopril | Dexamethasone | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
743,
24,
1220
]
],
[
[
743,
63,
870
],
[
870,
1,
1220
]
],
[
[
743,
63,
175
],
[
175,
40,
1220
]
],
[
[
743,
24,
167
],
[
167,
1... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB00046 | DB00176 | 1,179 | 529 | [
"DDInter940",
"DDInter770"
] | Insulin lispro | Fluvoxamine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Moderate | 1 | [
[
[
1179,
24,
529
]
],
[
[
1179,
24,
1424
],
[
1424,
62,
529
]
],
[
[
1179,
24,
1220
],
[
1220,
63,
529
]
],
[
[
1179,
24,
1466
],
[
1466,... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a minor interaction that can limit clinical effects when taken with Fluvoxamine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and De... |
DB00323 | DB00662 | 1,062 | 717 | [
"DDInter1829",
"DDInter1873"
] | Tolcapone | Trimethobenzamide | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1062,
24,
717
]
],
[
[
1062,
21,
28762
],
[
28762,
60,
717
]
],
[
[
1062,
24,
1594
],
[
1594,
24,
717
]
],
[
[
1062,
24,
1376
],
[
137... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Tolcapone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is c... | Tolcapone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trim... |
DB00425 | DB01075 | 558 | 1,376 | [
"DDInter1970",
"DDInter569"
] | Zolpidem | Diphenhydramine | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
558,
24,
1376
]
],
[
[
558,
24,
649
],
[
649,
63,
1376
]
],
[
[
558,
63,
128
],
[
128,
24,
1376
]
],
[
[
558,
24,
832
],
[
832,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine a... |
DB01075 | DB04868 | 1,376 | 478 | [
"DDInter569",
"DDInter1293"
] | Diphenhydramine | Nilotinib | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1376,
24,
478
]
],
[
[
1376,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1376,
21,
28762
],
[
28762,
60,
478
]
],
[
[
1376,
24,
271
],
[
271,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Co... | Diphenhydramine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Diphenhydramine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegr... |
DB00976 | DB11986 | 1,056 | 484 | [
"DDInter1758",
"DDInter648"
] | Telithromycin | Entrectinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
1056,
25,
484
]
],
[
[
1056,
62,
112
],
[
112,
23,
484
]
],
[
[
1056,
24,
466
],
[
466,
62,
484
]
],
[
[
1056,
25,
1135
],
[
1135,
... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Telithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Me... | Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide... |
DB00213 | DB00515 | 837 | 589 | [
"DDInter1388",
"DDInter387"
] | Pantoprazole | Cisplatin | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
837,
24,
589
]
],
[
[
837,
6,
17404
],
[
17404,
45,
589
]
],
[
[
837,
21,
28778
],
[
28778,
60,
589
]
],
[
[
837,
23,
1468
],
[
1468,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)"... | Pantoprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Cisplatin (Compound)
Pantoprazole (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Cisplatin (Compound)
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with P... |
DB00502 | DB05812 | 1,300 | 1,374 | [
"DDInter853",
"DDInter8"
] | Haloperidol | Abiraterone | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
1300,
25,
1374
]
],
[
[
1300,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1300,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
1300,
23,
112
],
[
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Abir... | Haloperidol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Haloperidol (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole an... |
DB00741 | DB11601 | 167 | 1,270 | [
"DDInter885",
"DDInter1889"
] | Hydrocortisone | Tuberculin purified protein derivative | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
167,
24,
1270
]
],
[
[
167,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
167,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
167,
1,
1486
],
[
1486,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Hydrocortisone may lead to a major life threatening interaction when taken wit... |
DB00594 | DB01075 | 863 | 1,376 | [
"DDInter68",
"DDInter569"
] | Amiloride | Diphenhydramine | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
863,
24,
1376
]
],
[
[
863,
24,
401
],
[
401,
24,
1376
]
],
[
[
863,
6,
8803
],
[
8803,
45,
1376
]
],
[
[
863,
21,
28921
],
[
28921,
... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Amiloride (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Diphenhydramine (Compound)
Amil... |
DB00557 | DB14568 | 252 | 982 | [
"DDInter895",
"DDInter1000"
] | Hydroxyzine | Ivosidenib | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
252,
25,
982
]
],
[
[
252,
23,
112
],
[
112,
23,
982
]
],
[
[
252,
24,
543
],
[
543,
24,
982
]
],
[
[
252,
64,
11
],
[
11,
25,
... | [
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lo... |
DB00880 | DB09112 | 359 | 1,455 | [
"DDInter360",
"DDInter1306"
] | Chlorothiazide | Nitrous acid | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
359,
24,
1455
]
],
[
[
359,
40,
674
],
[
674,
24,
1455
]
],
[
[
359,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
359,
24,
433
],
[
433,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
... | Chlorothiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a... |
DB00951 | DB08904 | 1,072 | 375 | [
"DDInter986",
"DDInter342"
] | Isoniazid | Certolizumab pegol | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
1072,
24,
375
]
],
[
[
1072,
24,
1047
],
[
1047,
24,
375
]
],
[
[
1072,
24,
1434
],
[
1434,
63,
375
]
],
[
[
1072,
63,
10
],
[
10,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Isoniazid may cause a moderate interaction that could exacerbate diseases when take... |
DB12095 | DB12141 | 179 | 971 | [
"DDInter1760",
"DDInter817"
] | Telotristat ethyl | Gilteritinib | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
179,
24,
971
]
],
[
[
179,
63,
1135
],
[
1135,
23,
971
]
],
[
[
179,
24,
466
],
[
466,
62,
971
]
],
[
[
179,
63,
1181
],
[
1181,
... | [
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
... | Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Darolutam... |
DB00258 | DB01165 | 666 | 1,539 | [
"DDInter270",
"DDInter1325"
] | Calcium acetate | Ofloxacin | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
666,
24,
1539
]
],
[
[
666,
24,
1467
],
[
1467,
1,
1539
]
],
[
[
666,
63,
1176
],
[
1176,
1,
1539
]
],
[
[
666,
24,
945
],
[
945,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Co... |
DB00927 | DB04855 | 1,559 | 540 | [
"DDInter712",
"DDInter602"
] | Famotidine | Dronedarone | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
1559,
24,
540
]
],
[
[
1559,
63,
347
],
[
347,
40,
540
]
],
[
[
1559,
24,
33
],
[
33,
40,
540
]
],
[
[
1559,
21,
28828
],
[
28828,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibutilide"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
... |
DB00196 | DB08867 | 600 | 807 | [
"DDInter743",
"DDInter1897"
] | Fluconazole | Ulipristal | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Minor | 0 | [
[
[
600,
23,
807
]
],
[
[
600,
25,
1135
],
[
1135,
62,
807
]
],
[
[
600,
23,
609
],
[
609,
23,
807
]
],
[
[
600,
24,
723
],
[
723,
2... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ulipristal"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Fluconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may ca... |
DB06414 | DB14723 | 655 | 159 | [
"DDInter703",
"DDInter1026"
] | Etravirine | Larotrectinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
655,
24,
159
]
],
[
[
655,
63,
222
],
[
222,
23,
159
]
],
[
[
655,
24,
466
],
[
466,
23,
159
]
],
[
[
655,
24,
741
],
[
741,
24,... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and D... |
DB00489 | DB08868 | 17 | 1,011 | [
"DDInter1704",
"DDInter737"
] | Sotalol | Fingolimod | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
17,
25,
1011
]
],
[
[
17,
21,
28859
],
[
28859,
60,
1011
]
],
[
[
17,
23,
578
],
[
578,
23,
1011
]
],
[
[
17,
25,
144
],
[
144,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Atrioventricular block"
],
[
"Atrioventricular block",
"{u} (Side Effect) is... | Sotalol (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Fingolimod (Compound)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when ta... |
DB00704 | DB09054 | 267 | 384 | [
"DDInter1263",
"DDInter905"
] | Naltrexone | Idelalisib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
267,
24,
384
]
],
[
[
267,
24,
1627
],
[
1627,
62,
384
]
],
[
[
267,
24,
72
],
[
72,
24,
384
]
],
[
[
267,
24,
725
],
[
725,
63,... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltro... |
DB00570 | DB14762 | 147 | 994 | [
"DDInter1936",
"DDInter1602"
] | Vinblastine | Risankizumab | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Moderate | 1 | [
[
[
147,
24,
994
]
],
[
[
147,
63,
1461
],
[
1461,
23,
994
]
],
[
[
147,
24,
4
],
[
4,
24,
994
]
],
[
[
147,
63,
58
],
[
58,
24,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesucci... |
DB08911 | DB08912 | 1,556 | 1,040 | [
"DDInter1842",
"DDInter462"
] | Trametinib | Dabrafenib | Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. ... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1556,
24,
1040
]
],
[
[
1556,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
1556,
7,
10351
],
[
10351,
46,
1040
]
],
[
[
1556,
18,
8911
],
[
89... | [
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Trametinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",... | Trametinib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Trametinib (Compound) upregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Dabrafenib (Compound)
Trametinib (Compound) downregulates NCAPH (Gene) and NCAPH (Gene) is downregulated by Dabrafenib (Compound)
Trametinib (Comp... |
DB01159 | DB01218 | 419 | 1,493 | [
"DDInter854",
"DDInter852"
] | Halothane | Halofantrine | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
419,
25,
1493
]
],
[
[
419,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
419,
62,
112
],
[
112,
23,
1493
]
],
[
[
419,
63,
770
],
[
770,
... | [
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Halofan... | Halothane (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Halothane may ... |
DB11703 | DB11817 | 405 | 1,259 | [
"DDInter9",
"DDInter165"
] | Acalabrutinib | Baricitinib | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
405,
25,
1259
]
],
[
[
405,
76,
1274
],
[
1274,
24,
1259
]
],
[
[
405,
64,
598
],
[
598,
24,
1259
]
],
[
[
405,
63,
949
],
[
949,
... | [
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Acalabrutinib may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Acalabru... |
DB08870 | DB11932 | 850 | 327 | [
"DDInter228",
"DDInter3"
] | Brentuximab vedotin | Abametapir (topical) | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
850,
24,
327
]
],
[
[
850,
63,
168
],
[
168,
24,
327
]
],
[
[
850,
24,
283
],
[
283,
63,
327
]
],
[
[
850,
24,
292
],
[
292,
24,... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomi... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Aba... |
DB01244 | DB06605 | 762 | 1,409 | [
"DDInter192",
"DDInter108"
] | Bepridil | Apixaban | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
762,
24,
1409
]
],
[
[
762,
6,
4973
],
[
4973,
45,
1409
]
],
[
[
762,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
762,
25,
1670
],
[
1670,... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Bepridil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Bepridil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Apixaban (Compound)
Bepridil (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Bepridil may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a modera... |
DB00708 | DB01619 | 1,454 | 830 | [
"DDInter1718",
"DDInter1441"
] | Sufentanil | Phenindamine | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1454,
24,
830
]
],
[
[
1454,
24,
537
],
[
537,
40,
830
]
],
[
[
1454,
63,
13
],
[
13,
24,
830
]
],
[
[
1454,
24,
104
],
[
104,
1... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction th... |
DB00398 | DB01268 | 79 | 1,151 | [
"DDInter1702",
"DDInter1731"
] | Sorafenib | Sunitinib | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
79,
24,
1151
]
],
[
[
79,
5,
11570
],
[
11570,
44,
1151
]
],
[
[
79,
6,
10365
],
[
10365,
45,
1151
]
],
[
[
79,
34,
6732
],
[
6732,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Sorafenib",
"{u} (Compound) treats {v} (Disease)",
"kidney cancer"
],
[
"kidney cancer",
"{u} (Disease) is treated... | Sorafenib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Sunitinib (Compound)
Sorafenib (Compound) binds STK10 (Gene) and STK10 (Gene) is bound by Sunitinib (Compound)
Sorafenib (Compound) binds MAP2K5 (Gene) and Sorafenib (Compound) upregulates MAP2K5 (Gene) and MAP2K5 (Gene) is bo... |
DB00485 | DB00563 | 916 | 663 | [
"DDInter541",
"DDInter1174"
] | Dicloxacillin | Methotrexate | One of the penicillins which is resistant to penicillinase. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Major | 2 | [
[
[
916,
25,
663
]
],
[
[
916,
6,
15333
],
[
15333,
45,
663
]
],
[
[
916,
21,
28681
],
[
28681,
60,
663
]
],
[
[
916,
25,
126
],
[
126,
... | [
[
[
"Dicloxacillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
],
[
[
"Dicloxacillin",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
... | Dicloxacillin (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Methotrexate (Compound)
Dicloxacillin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Dicloxacillin may lead to a major life threatening interaction when taken with Warfa... |
DB09048 | DB12010 | 555 | 214 | [
"DDInter1284",
"DDInter785"
] | Netupitant | Fostamatinib | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
555,
24,
214
]
],
[
[
555,
63,
976
],
[
976,
24,
214
]
],
[
[
555,
64,
866
],
[
866,
24,
214
]
],
[
[
555,
25,
1362
],
[
1362,
2... | [
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[... | Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Netupitant may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may ... |
DB00563 | DB01610 | 663 | 248 | [
"DDInter1174",
"DDInter1912"
] | Methotrexate | Valganciclovir | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
663,
24,
248
]
],
[
[
663,
24,
1295
],
[
1295,
1,
248
]
],
[
[
663,
21,
29209
],
[
29209,
60,
248
]
],
[
[
663,
63,
1101
],
[
1101,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
]... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir (Compound) resembles Valganciclovir (Compound)
Methotrexate (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Methotrexate may cause a moder... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.